In vitro activities of selected new and long-acting cephalosporins against Pasteurella multocida
Antimicrobial Agents and Chemotherapy
|February 1, 1986
Abstract:
The activities of six agents commonly used in treating infections of the skin and soft tissues and the action of selected cephalosporins against 15 isolates of Pasteurella multocida were assessed by a macro-broth dilution method. Broad-spectrum cephalosporins, including ceftriaxone and cefixime, had excellent in vitro activities (MIC less than or equal to 0.098) against the isolates tested.
Insights
Broad-spectrum cephalosporins like ceftriaxone and cefixime show excellent in vitro activity against skin infection-causing Pasteurella multocida isolates. This finding supports their use in treating soft tissue infections caused by this common pathogen.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Skin and soft tissue infections (SSTIs) are common clinical challenges.
- Pasteurella multocida is a significant pathogen in SSTIs, particularly following animal bites.
- Effective antimicrobial agents are crucial for managing these infections.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of commonly used agents against Pasteurella multocida.
- To assess the efficacy of selected cephalosporins against clinical isolates of Pasteurella multocida.
Main Methods:
- A macro-broth dilution method was employed for susceptibility testing.
- Six common antimicrobial agents were tested.
- Fifteen clinical isolates of Pasteurella multocida were analyzed.
Main Results:
- Broad-spectrum cephalosporins demonstrated excellent in vitro activity.
- Ceftriaxone and cefixime exhibited minimal inhibitory concentrations (MICs) less than or equal to 0.098 µg/mL.
- These results indicate high susceptibility of the tested Pasteurella multocida isolates to these agents.
Conclusions:
- Broad-spectrum cephalosporins, specifically ceftriaxone and cefixime, are highly effective in vitro against Pasteurella multocida.
- These findings support the continued use of these cephalosporins for treating Pasteurella multocida-related skin and soft tissue infections.
